AXGN

AxoGen, Inc.

NASDAQ

Add Alert

AXGN

AxoGen, Inc.

NASDAQ

Add Alert

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Newer

eddie51

08/09/13 7:34 PM

Post #22

Re: #21: @Renee - AXGN: Listed on NCM (AXGN)**; Pending offering

Don't think this stock will go anywhere. JMHO

Renee

08/09/13 7:28 AM

Post #21

AXGN: Listed on NCM (AXGN)**; Pending offering

http://www.otcbb.com/asp/dailylist_detail.asp?d=08/08/2013&mkt_ctg=OTCBB

SPM555

04/30/13 4:52 PM

Post #20

10q out today, liking the numbers a lot! Getting ready for a breakout, imo.

Revenues for the three months ended March 31, 2013 increased 29.6% to approximately $2,143,000 as compared to approximately $1,653,000 for the three months ended March 31, 2012 . This increase was primarily a result of sales to new accounts and increased product usage by existing accounts.

Gross profit for the three months ended March 31, 2013 increased 30.4% to approximately $1,583,000 as compared to approximately $1,214,000 for the three months ended March 31, 2012 , primarily attributable to the increased revenues in the first quarter of 2013, manufacturing efficiencies and a product price increase instituted in March 2013 , partially offset by an increase in the inventory reserve. As a result, gross margin also improved to 73.9% for the three months ended March 31, 2013 as compared to 73.4% for the same period in 2012.

SPM555

04/18/13 5:36 PM

Post #19

Looking very solid, looks like a flag pattern is setting up to bust out.

http://ichartpennystocks.com/axgn-axogen-inc-breakout-trigger-5-15/

Immie

04/12/13 4:37 PM

Post #18

Re: #17: @Immie - AxoGen, Inc. Reports Record 2012 Revenues

I am a idiot.... freaking hit 6 bucks today.

Immie

03/12/13 9:57 PM

Post #17

AxoGen, Inc. Reports Record 2012 Revenues
7:36p ET March 12, 2013 (Business Wire)
--Revenue for full year 2012 increased 59% to $7.69 million from $4.85 million for full year 2011

--Gross profit for full year 2012 increased $3.31 million, or 136%, to $5.73 million compared with full year 2011

--Gross margins for full year 2012 were 75%

--Fourth Quarter 2012 Highlights

--Revenue for 4Q12 was $2.04 million, a 50% increase over 4Q11

--Gross profit for 4Q12 was $1.58 million versus $0.83 million for 4Q11

AxoGen, Inc. (OTCBB: AXGN) a leading regenerative medicine company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration, today reported revenues for the year ended December 31, 2012 of $7.69 million, a 59% increase over the $4.85 million reported during the same period in 2011. In addition, the Company reported a net loss for 2012 of $9.42 million, or ($0.85) per common share, compared to a net loss of $10.25 million, or ($2.77) per common share, reported during the same period in 2011.

"AxoGen's revenue growth is an affirmation of market demand and the direct result of an increase in the number of surgeons and hospitals using our peripheral nerve repair technologies," stated Karen Zaderej, Chief Executive Officer of AxoGen. "Our strategy is to provide education and clinical evidence to surgeons on the value of new peripheral nerve treatment options to drive adoption of our products. That strategy was evident with the publication of data for Avance(R) Nerve Graft from the Ranger(R) Study in two leading, peer-reviewed journals, Microsurgery and The Journal of Hand Surgery. Further, expanded data from the RANGER(R) Study was presented at the American Association for Hand Surgery conference in January 2013, which received strong visibility among hand surgeons."

Ms. Zaderej continued, "In 2012, we successfully completed a $20.8 million financing with PDL that strengthened our balance sheet, and provided the funds to expand training of our sales team, to increase our marketing efforts and add additional sales associates. We believe these initiatives position AxoGen well for acceleration of growth in 2013."

Revenue

Revenues for the year ended December 31, 2012 increased 59% to approximately $7,692,00 as compared to approximately $4,849,000 for the year ended December 31, 2011 principally due to a greater number of customers utilizing AxoGen products.

Gross Profit

Gross profit for the year ended December 31, 2012 reached $5.73 million, a 136% increase, compared to $2.42 million for the same period in 2011. This increase is due, in part, to increased revenues and gross margins, and not incurring the $0.8 million in inventory and raw-materials write-offs experienced in 2011. Also, in 2011 we had higher processing and testing fees, travel costs and temporary labor costs due to the resumption of the manufacturing of Avance(R) Nerve Graft that were not incurred in 2012. Gross profit margin for 2012 was 75%.

Sales and Marketing Expenses

Sales and marketing expenses increased 57.2% to approximately $6,884,000 for the year ended December 31, 2012 as compared to approximately $4,379,000 for the year ended December 31, 2011. This increase was primarily due to expanded marketing activity and an increase in the number of direct representatives. As a percentage of revenues, sales and marketing expenses were 89.4% for the year ended December 31, 2012 compared to 90.3% for the year ended December 31, 2011. Sales and marketing expenses as a percentage of revenue remaining flat between yearly periods was primarily a result of revenue increases in 2012 being offset by increased expenses.

General and Administrative Expenses

General and administrative expenses increased 21.0% to approximately $5,221,000 for the year ended December 31, 2012 as compared to approximately $4,316,000 for the year ended December 31, 2011. As a percentage of revenues, general and administrative expenses decreased to 67.9% for the year ended December 31, 2012 compared to 89.0% the year ended December 31, 2011. The increase in aggregate dollars spent was a result of hiring and costs related to being a public company, offset by a savings in certain professional fees and finance costs. As a percentage of revenue, general and administrative expenses decreased as the increase in aggregate dollars spent was absorbed by the increase in revenues.

Research and Development

Research and development expenses increased to approximately $1,427,000 in the year ended December 31, 2012 as compared to approximately $697,000 for the year ended December 31, 2011. Development includes AxoGen's clinical efforts and other investments in data that help support the value of our products. A large portion of the increase in research and development expenses from 2011 to 2012 related to expenditures for such clinical activity.

Financial Liquidity

At December 31, 2012, the Company had approximately $13.91 million in cash and cash equivalents and approximately $21.58 million in long-term debt outstanding.

On October 5, 2012, the Company entered into a Revenue Interests Purchase Agreement with PDL BioPharma Inc., under which the Company received $20.8 million in cash, certain proceeds of which were used to repay existing debt and expenses related to the transaction.

Greg Freitag, AxoGen's CFO and General Counsel stated, "The PDL transaction provided capital to the Company without the issuance of any dilutive equity. By leveraging this capital into our sales and marketing organization, we expect to see the continued increase of shareholder value. The structure of the PDL transaction was intended to maximum available funds in the near term and allow for flexibility in the longer term."

Earnings Call Information

As previously announced, AxoGen, Inc. management will review its year end 2012 and fourth quarter 2012 financials during a conference call scheduled for March 13, 2013 at 10:00 AM Eastern Time. The conference call information is as follows:

Conference dial-in: 877-709-8150
International dial-in: 201-689-8354
Conference Name: AxoGen 2012 Fourth Quarter & Year End Results
Conference ID: 00409696
Conference Call Webcast: www.axogeninc.com/investors.html

Following the live call, a replay will be available on the Company's website, www.axogeninc.com, under the "Investors" page.

About AxoGen, Inc.

AxoGen (OTCBB: AXGN) is a regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions. The Company's innovative approach to regenerative medicine has resulted in first-in-class products that will define their product categories. AxoGen's products offer a full suite of surgical nerve reconstruction solutions including Avance(R) Nerve Graft, the only commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard(R) Nerve Connector, a porcine submucosa ECM coaptation aid for tensionless repair of severed nerves, and AxoGuard(R) Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce coaptation sites while preventing soft tissue attachments. For more information, visit our website at www.axogeninc.com.

AxoGen is the parent of its wholly owned operating subsidiary, AxoGen Corporation. AxoGen's principal executive office and operations are located in Alachua, FL. To receive email alerts directly from AxoGen, please click here www.axogeninc.com/emailalerts.html.

Cautionary Statements Concerning Forward-Looking Statements

This Press Release contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "projects", "forecasts", "continue", "may", "should", "will" variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding product development, product potential, financial performance, sales growth, product adoption, market awareness of our products and data validation. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen's business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen's filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Immie

03/12/13 9:43 PM

Post #16

Re: #15: @Immie - 4 seems to be previous resistance.... watching to

$3.9900 500 OBB 15:42:54
$3.9900 1,000 OBB 15:38:00
$3.9900 400 OBB 15:18:20
$3.9900 250 OBB 15:11:35
$3.9500 100 OBB 12:17:03
$3.9500 500 OBB 12:16:23
$4.0000 900 OBB 11:15:47
$4.0000 800 OBB 11:14:41
$4.0000 500 OBB 11:14:41
$4.0000 500 OBB 11:14:41
$4.0000 1,000 OBB 11:14:38
$3.9500 500 OBB 10:52:27
$3.9500 100 OBB 10:41:43
$3.8500 2,833 OBB 09:31:26
$3.8500 1,000 OBB 09:29:46
$3.8000 235 OBB 03/11
$3.8000 504 OBB 03/11
$3.9900 10,800 OBB 03/08
$3.9000 800 OBB 03/08
$3.9400 100 OBB 03/08
$3.8900 800 OBB 03/08
$3.8800 100 OBB 03/08
$3.8000 850 OBB 03/08
$3.6900 100 OBB 03/08
$3.6800 500 OBB 03/08
$3.6800 1,561 OBB 03/08
$3.6900 1,000 OBB 03/08
$3.6900 450 OBB 03/08
$3.6900 550 OBB 03/08
$3.6800 173 OBB 03/08

Immie

03/09/13 3:35 PM

Post #15

4 seems to be previous resistance.... watching to see if it surpasses that level.

Stockguru55

07/16/12 9:43 PM

Post #14

CFO Spoke in Boston 7/13 to Broker Group Told Very strong Growth Story and was well recieved

Stockguru55

07/16/12 9:40 PM

Post #13

REad About the New Sales and Distribution Opportunities World Wide

Stockguru55

07/16/12 9:39 PM

Post #12

CEO Presented in NYC At the JMP HealthCare Conference
Please see attached link:

http://wsw.com/webcast/jmp18/register.aspx?conf=jmp18&page=axgn.ob&url=http%3A//wsw.com/webcast/jmp18/axgn.ob/

--

Stockguru55

07/16/12 3:19 PM

Post #11

Great News Today, International Sales have started to Italy
Read News

cockrellgroup

05/30/12 11:50 AM

Post #9

Record 1Q Sales: Nerve Regeneration Products Gaining Traction - Seeking Alpha Click Here

Penny Roger$

05/09/12 6:31 AM

Post #8

MissionIR

04/03/12 3:38 PM

Post #7

AXGN Poised For Strong Growth In Regenerative Medicine

Nerve damaging injuries and surgeries can lead to a life of despair for the patient, leaving them with limited, or no, ability to move or even experience the feeling of touch. Recent advances in the field of regenerative medicine are giving hope to those suffering the debilitating effects of nerve injuries. As an emerging player in the area, AxoGen Inc. (AXGN) is poised to significantly contribute to this cutting-edge science.

Regenerative medicine enables the repair, restoration or replacement of tissue or organ systems of the body. Peripheral nerves provide the pathways for both motor and sensory signals between the central nervous system and target organs, regulating movement and touch. Traditionally, when peripheral nerves are damaged, patients have been presented with few medical options that offer meaningful recoveries.

AxoGen's proprietary products give surgeons new alternatives to repair damaged peripheral nerves. The company's products include AxoGuard® Nerve Connector, AxoGuard® Nerve Protector and Avance® Nerve Graft. AxoGuard® Nerve Connector is a coaptation aid to reconnect severed nerves, and AxoGuard® Nerve Protector protects nerves as the body heals after surgery. Avance® Nerve Graft, which is regarded as the first and only commercially available processed nerve allograft, bridges nerve gaps in severed nerves.

Hundreds of peripheral nerve injuries occur every day as a result of car crashes, power tool accidents and military combat. AxoGen's products position it to be able to tap into this large and growing peripheral nerve repair market.

Ladenburg Thalmann & Co., Inc. analyst Jeffrey Cohen stated, "We would currently estimate that there are approximately 140,000 to 180,000 annual [autograph] procedures of the sural nerve in the United States. Coupled with other potential indications for usage, we believe that the market size for Avance in the U.S. to be approximately $500 million. The market for the rest of world could potentially double the size of the market."

Patients who suffer from these types of injuries, which number more than 700,000 a year, have had few options for a meaningful recovery. These challenging injuries have traditionally been repaired by surgeons who transplant a healthy nerve from another area in the patient's body to the nerve repair site. This creates an additional procedure that can lead to scarring, potential loss of feeling and pain in the area from which the nerve was removed. AxoGen's products do away with these issues.

The Avance® Nerve Graft was recently the topic of a clinical study led by The Buncke Clinic in San Francisco. Called the RANGER study, it included 12 centers and 25 surgeons making it the largest multi-center study in peripheral nerve reconstruction. The findings were published in the January 2012 issue of study.

The principal investigator for the study was Dr. Darrell Brooks, a plastic surgeon with The Buncke Clinic. Calling the clinical study results a 'paradigm shift,' Brooks noted that the information he now uses to counsel his patients before their surgeries will change.

"It is commonly accepted among surgeons who do peripheral nerve repair that success of surgery depends on the type of injury, length of nerve discontinuity, the patient's age and the type of nerve," Dr. Brooks has stated. "Our study findings show that with processed nerve allograft, patients can have meaningful recovery regardless of these factors."

There were no reported implant complications, tissue rejections or adverse events related to the use of the processed nerve allografts. Trial participants included subjects from Level 1 trauma centers, academic medical centers, military medical centers and community medical centers.

To further boost its presence in the regenerative medical field, AxoGen last year merged with LecTec. Although there were increased expenses as a result of the merger that contributed to an operating loss of $9.2 million for 2011, the company's revenues and gross profit increased. Revenues increased 61% to $4.9 million in 2011 compared to 2010. The company's gross profit increased 49% to $2.4 million for the same period.

AxoGen is poised to continue to improve its financial results. It has committed to specific growth areas, including investing in its sales force and expanding clinical and scientific data regarding the performance of its products.

Moving forward, the company intends to use its capital resources to continue to improve shareholder value with focused commercialization strategies to increase awareness and adoption of the new regenerative medicine technologies for peripheral nerve repair.

Jeffrey Cohen initiated coverage on AxoGen shares with a BUY rating and a target price of $4.50 in January 2012. That price is based on a discounted fiscal 2013 Enterprise Value to Revenue (EV/R) multiple compared to several of AxoGen's peers.

As of the time of writing, the company was trading at $2.70.

Over a series of articles, the impact of AxoGen's products will be examined. This includes the story of a 10-year old boy who suffered nerve damage to his arm after an ATV accident.

Bobwill59

11/12/09 7:34 PM

Post #5

I also found out today that lect has many more patents int he US and Internationally.
Bob

stervc

11/12/09 4:57 PM

Post #4

About LECT...

About LecTec Corporation

LecTec Corporation is an intellectual property licensing and holding company. The Company’s primary focus is to derive royalty and other income from patents that the Company owns based on its advanced skin interface technologies. The Company was an innovator in hydrogel–based topical delivery of therapeutic over–the–counter medications, which provide alternatives to topical creams and ointments. A hydrogel is a gel–like material having an affinity for water and similar compounds. These gels are ideal for delivering medication onto the skin. The Company holds multiple domestic and international patents on its hydrogel technology.

v/r
Sterling

stervc

11/12/09 4:55 PM

Post #3

From the Victory PR...

With this LECT victory...

http://finance.yahoo.com/news/LecTec-Corporation-and-Endo-bw-3060535446.html?x=0&.v=1
...the Company’s dependence on royalty payments from Novartis Consumer Health, Inc., which recently re–launched an adult vapor patch licensed by the Company, the Company’s dependence on key personnel and Board of Director members, the Company’s pending patent infringement litigation against Chattem, Inc. (NASDAQ: CHTT - News), Johnson & Johnson Consumer Company, Inc., a subsidiary of Johnson & Johnson (NYSE: JNJ - News), and Prince of Peace Enterprises, Inc., the issuance of new accounting pronouncements, the availability of opportunities for licensing agreements related to patents that the Company holds, limitations on market expansion opportunities, and other risks and uncertainties detailed from time to time in the Company’s filings with the Securities and Exchange Commission, and particularly as described in the “Risk Factors” included in our Form 10–K for the year ended December 31, 2008. ...

v/r
Sterling

stervc

11/12/09 4:52 PM

Post #2

With LECT...

A good friend brought LECT to my attention. I think the potential will continue to be made known as they win more and more cases. This first victory is huge. IMHO

v/r
Sterling

stervc

11/12/09 4:50 PM

Post #1

LECT $23 Million Patent Settlement with Endo...

http://philadelphia.bizjournals.com/philadelphia/stories/2009/11/09/daily34.html?ana=yfcpc
http://finance.yahoo.com/news/LecTec-Corporation-and-Endo-bw-3060535446.html?x=0&.v=1
LecTec Corporation and Endo Pharmaceuticals Inc. Settle Patent Dispute

TEXARKANA, Texas--(BUSINESS WIRE)--LecTec Corporation (OTCBB: LECT - News) announced today that it has reached a settlement with Endo Pharmaceuticals Inc. on outstanding patent litigation related to LecTec’s U.S. Patent Nos. 5,536,263 and 5,741,510. Endo Pharmaceuticals has agreed to make a one–time, $23 million payment for the exclusive license to these two patents for use in the field of prescription pain medicines and treatment. “LecTec is pleased to have reached an agreement with Endo Pharmaceuticals which avoids the uncertainties of litigation and provides LecTec with the capital to explore the opportunities in its patent portfolio,” said Judd Berlin, chief executive officer of LecTec.

LecTec filed a patent infringement action in U.S. District Court in July 2008 against Endo Pharmaceuticals and others in the topical medicated patch business alleging patent infringement of the core structure and composition claims of two of LecTec’s patents.

About LecTec Corporation

LecTec Corporation is an intellectual property licensing and holding company. The Company’s primary focus is to derive royalty and other income from patents that the Company owns based on its advanced skin interface technologies. The Company was an innovator in hydrogel–based topical delivery of therapeutic over–the–counter medications, which provide alternatives to topical creams and ointments. A hydrogel is a gel–like material having an affinity for water and similar compounds. These gels are ideal for delivering medication onto the skin. The Company holds multiple domestic and international patents on its hydrogel technology.

Cautionary Statements

This press release contains forward–looking statements concerning possible or anticipated future results of operations or business developments which are typically preceded by the words “believes,” “wants,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. Such forward-looking statements are subject to risks and uncertainties, which could cause results or developments to differ materially from those, indicated in the forward–looking statements. Such risks and uncertainties include, but are not limited to, the Company’s dependence on royalty payments from Novartis Consumer Health, Inc., which recently re–launched an adult vapor patch licensed by the Company, the Company’s dependence on key personnel and Board of Director members, the Company’s pending patent infringement litigation against Chattem, Inc. (NASDAQ: CHTT - News), Johnson & Johnson Consumer Company, Inc., a subsidiary of Johnson & Johnson (NYSE: JNJ - News), and Prince of Peace Enterprises, Inc., the issuance of new accounting pronouncements, the availability of opportunities for licensing agreements related to patents that the Company holds, limitations on market expansion opportunities, and other risks and uncertainties detailed from time to time in the Company’s filings with the Securities and Exchange Commission, and particularly as described in the “Risk Factors” included in our Form 10–K for the year ended December 31, 2008.

Contact:
LecTec Corporation
Bill Johnson, Controller
903–832–0993

************************************************************

v/r
Sterling